Martin J. Edelman, Ming T. Tan, Mary J. Fidler, Rachel E. Sanborn, Greg Otterson, Lecia V. Sequest, Tracey L. Evans, Bryan J. Schneider, Roger Keresztes, Johs S. Rogers, Jorge Antunez de Mayolo, Josephine Feliciano, Yang Yang, Michelle Medeiros, and Sara L. Zaknoen: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer Journal of Clinical Oncology 33 (2): 189-194,2015.
TL Evans: Chemotherapy in Advanced Non-small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients with Poor Performance Status The American Journal of Hematology/Oncology 11 (7): 1-5,2015.
Preeti Sudheendra, Beth Gilbert, Dawna Gillespie, Mary Coniglio, Tracey L. Evans: Improving telephone management of patient clinical concerns Poster presented at ASCO Quality Care Symposium,
J Clin Oncol 32, 2014 (suppl 30; abstr 137) : 2014.
Bauml Joshua, Langer Corey J, Evans Tracey, Garland Sheila N, Desai Krupali, Mao Jun J: Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 22 (9): 2465-72,2014.
Stephen Joseph Bagley, Corey J. Langer, Charu Aggarwal, Tracey L. Evans, Evan W. Alley, Roger B. Cohen, Suhong Zhang, Lynn Werner, Ian A Blair, Alexander Steven Whitehead, Anil Vachani: Pre-treatment 5-methyltetrahydrofolate levels and response to pemetrexed in stage IV adenocarcinoma of the lung J Clin Oncol 33 : abstract 8037,2015.
Helena Alexandra Yu, Geoffrey R. Oxnard, Alexander I. Spira, Leora Horn, Jared Weiss, Yan Feng, Howard Jack West, Giuseppe Giaccone, Tracey L. Evans, Ronan Joseph Kelly, Tanya Fleege, Srinivasu Poondru, Fei Jie, Koji Aoyama, Margaret A. Foley, Debbie Whitcomb, Anne Therese Keating, Andrew P. Krivoshik: Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC J Clin Oncol 33 : abstract 8083,2015.
Saman Ahmed, Charu Aggarwal, Rosemarie Mick, Trisha M Sterlicchi, Stephan Kadauke, Christofer Gault, Roger B. Cohen, Tracey L. Evans, Joshua Bauml, Charuhas Deshpande, Drew A. Torigian, Jayaram Udupa, Corey J. Langer, Jennifer J. Morrissette: Association of TP53 mutation status with clinical outcomes stratified by sensitive and non sensitive EGFR mutation, in non-small cell lung cancer (NSCLC). J Clin Oncol 33 : abstract e19076,2015.